Table 2. Outcomes.
| Characteristic | No. (%) | |
|---|---|---|
| TRUS-guided biopsy | MRI-guided biopsy | |
| Participants, No. | 226 | 227 |
| MRI result | ||
| PI-RADS score | NA | |
| 1-2/negative | 83 (38) | |
| 3-5/positive | 138 (61) | |
| 3 | 26 (12) | |
| 4 | 82 (38) | |
| 5 | 30 (14) | |
| Biopsy | ||
| Did not undergo | 24 (11) | 91 (40) |
| Underwent | 202 (89) | 136 (60) |
| No cancer on biopsy | 86 (38) | 34 (15) |
| Cancer | ||
| GG1 or none (including no biopsy) | 159 (70) | 148 (65) |
| GG1 | 49 (22) | 23 (10) |
| GG2 | 42 (19) | 49 (22) |
| GG2 or highera | 67 (30) | 79 (35) |
| GG3 | 17 (8) | 18 (8) |
| GG3 or higher | 25 (11) | 30 (13) |
| GG4 | 3 (1) | 5 (2) |
| GG5 | 5 (2) | 7 (3) |
Abbreviations: GG, International Society of Urological Pathology grade group; MRI, multiparametric magnetic resonance imaging; NA, not applicable; PI-RADS, Prostate Imaging Reporting and Data System; TRUS, transrectal ultrasonography.
a
Primary outcome.